ClinicalTrials.gg
RecruitingNCT07102160CLEAR-VIEW XTUpdated Oct 20, 2026

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

An observational study in Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature and Venous Embolism, sponsored by Argon Medical Devices. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Argon Medical Devices · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 20, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
185
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 246 studies in Venous Thrombosis with a site in United States — 23 open to participants now, 31 under way, 5 of them phase 3. Venous Thrombosis · United States.

Planned enrollment
36th of 60
185 · median 221
Started
2026
with 10 others
Observational
61 of 246
6 open now
Primary completion
2029-06
later than 25 of 30 live
Registered
233rd of 246
by date

Among the 246 studies in Venous Thrombosis with a site in United States, this one is the 36th largest by planned enrollment of the 60 observational ones that give a count, is one of 11 that started in 2026, is one of 61 observational ones, reaches primary completion later than 25 of the 30 other live ones, and was the 233rd registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

23 of the 246 studies in Venous Thrombosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Venous Thrombosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.

03

Conditions studied

  • Deep Vein Thrombosis (DVT)
  • Thrombus in the Peripheral Venous Vasculature
  • Venous Embolism
  • Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts

Keywords

  • Aspiration Thrombectomy
  • Deep Vein Thrombosis (DVT)
  • Peripheral VTE
  • Venous thromboembolism
  • Percutaneous mechanical thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enroll up to 185 adult participants undergoing percutaneous mechanical thrombectomy using the Cleaner Vac® Thrombectomy System for the treatment of thrombus in the peripheral venous vasculature.

Participants must be at least 18 years old and undergoing frontline treatment with the Cleaner Vac® device. The DVT subgroup must have symptomatic, imaging-confirmed DVT involving the femoral-popliteal, common femoral, iliac veins, or inferior vena cava (IVC), with symptom onset within 6 weeks and imaging confirmation within 14 days of the index procedure.

The study population is intended to reflect a real-world, all-comers cohort treated across up to 50 investigational sites in the United States.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria to be eligible for the study:

  1. At least 18 years of age at the time of consent.
  2. Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body.
  3. Written obtained through the IRB-approved ICF.

    For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:

  4. Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:

    1. Femoral-popliteal vein
    2. Common femoral vein
    3. Iliac vein
    4. Inferior Vena Cava (IVC)
  5. DVT diagnosis confirmed by imaging within 14 days of the index procedure.
  6. Symptomatic DVT with onset within 6 weeks of enrollment.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if any of the following criteria are met:

  1. to systemic or therapeutic doses of anticoagulants.
  2. Contraindication to iodinated contrast that cannot be adequately premedicated.
  3. less than 1 year due to advanced , as determined by the investigator at the time of enrollment
  4. Patients that are pregnant.
  5. Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period.
  6. Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure.
  7. Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins.
  8. Known history of a Patent Foramen Ovale (PFO).
  9. \< 8.0 g/dL, > 2.0 before warfarin was started, or \< 50,000/µl which cannot be corrected prior to enrollment.
  10. Severe renal impairment (estimated \< 30 ml/min) in patients who are not yet on dialysis. Patients with GFR \<30 ml/min who are already on dialysis can be enrolled.
  11. Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:

    1. High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure \<90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP \<90 mmHg or a drop ≥40 mmHg for >15 minutes not due to other causes)
    2. Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin).
  12. Complete infrarenal IVC occlusion.
  13. Chronic non-ambulatory status.
  14. Current enrollment in another device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
185 participants (estimated)
Patient registry
No

Groups and cohorts

  • DVT Subgroup

    This is a defined cohort focused on patients with lower extremity proximal deep vein thrombosis (DVT) who will undergo treatment with Cleaner Vac® Thrombectomy System. Participants will complete required follow-up at discharge and at 1, 6, 12, and 24 months.

    Device: Aspiration thrombectomy system

Interventions

  • DeviceAspiration thrombectomy system

    The Cleaner Vac® Thrombectomy System is a percutaneous mechanical aspiration thrombectomy device designed for the removal of fresh, soft thrombi and emboli from the peripheral venous vasculature. The system includes an aspiration canister with integrated pump, an 18F aspiration catheter, a handpiece with aspiration control lever, a dilator, and an optional flushing adapter. The device operates via controlled suction to extract thrombus and restore venous patency.

06

What researchers measure

Primary outcomes

  1. Technical Success

    ≥75% thrombus removal in the target venous segment, assessed by change in Marder Score

    Time frame: At the time of the index procedure

  2. Composite rate of Major Adverse Events (MAEs) within 30 days post-procedure

    Time frame: 30 days post-index procedure

Secondary outcomes

  1. Freedom from Device- or Procedure-Related Serious Adverse Events (SAEs)

    Time frame: 30 days post-procedure

  2. Post-Thrombotic Syndrome Severity

    Assessment of post-thrombotic syndrome using the Villalta score, which combines patient-reported symptoms and clinician-assessed signs to generate a composite score. A score ≥5 indicates the presence of post-thrombotic syndrome, with higher scores reflecting greater severity.

    Time frame: Up to 24 months

  3. Venous patency

    Presence of flow in the treated venous segment without re-thrombosis

    Time frame: From 30 days post-treatment to the end of the study period

  4. Need for Target Vessel Reintervention

    Any additional endovascular or surgical procedure to address recurrent/residual thrombus

    Time frame: From date of index procedure up to 24 months

  5. Numeric Pain Rating Scale

    Self-reported health status measured using the Numeric Pain Rating Scale questionnaire, which evaluates current, best, and worst pain experienced on a 0 (minimum) to 10 (maximum) level scale. 10 having worst pain imaginable.

    Time frame: Up to 24 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2029, 40 months after the start.

Of 127 observational studies under Venous Thrombosis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 82. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Aug 3, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Indiana University Health · Indianapolis, United States
Show 1 removed
  • Baycare Health System · Tampa, United States
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • St. Elizabeth Healthcare - Edgewood · Edgewood, United StatesContact removed c•••@stelizabeth.com · •••5473
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site added, 1 site removed
    Show site
    • Indiana University Health · Indianapolis, United States
    Show 1 removed
    • Baycare Health System · Tampa, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • St. Elizabeth Healthcare - Edgewood · Edgewood, United StatesContact removed c•••@stelizabeth.com · •••5473
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07102160
Lead sponsor
Argon Medical Devices
Collaborators
Avania, Medical Metrics Diagnostics, Inc
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Feb 4, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Esther Ajasa, MS
Contact
clinical@argonmedical.com
469-423-2280
Holly Harrison
Contact
clinical@argonmedical.com
(469) 731-3561
Pete Stibbs
study director · Argon Medical Devices

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion